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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Chilean Span-
ish language. The reading comprehension of the questionnaire was tested in ten JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, 
floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, and construct validity (convergent and 
discriminant validity). A total of 49 JIA patients (12.2% systemic, 24.5% oligoarticular, 22.5% RF-negative polyarthritis, 
40.8% other categories) and 70 healthy children, were enrolled. The JAMAR components discriminated well healthy subjects 
from JIA patients. All JAMAR components revealed good psychometric performances. In conclusion, the Chilean Spanish 
version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical 
practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Chilean Spanish parent, child/adult ver-
sion of the Juvenile Arthritis Multidimensional Assessment 
Report (JAMAR) [1] in patients with juvenile idiopathic 
arthritis (JIA). The JAMAR assesses the most relevant 
parent/patient reported outcomes in JIA, including overall 
well-being, functional status, health related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with illness 
outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Chilean Spanish language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] enrolled from November 2011 to 
October 2013. Children were recruited after Ethics Commit-
tee approval and consent from at least one parent.
The JAMAR
The JAMAR (1) includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy children 
and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption [mean and standard deviation 
(SD( equivalence]; the second Likert assumption or equal 
items–scale correlations (Pearson r: all items within a 
scale should contribute equally to the total score); third 
Likert assumption (item internal consistency or linearity 
for which each item of a scale should be linearly related 
to the total score that is 90% of the items should have 
Pearson r ≥ 0.4); floor/ceiling effects (frequency of items 
at lower and higher extremes of the scales, respectively); 
internal consistency, measured by the Cronbach’s alpha, 
interscale correlation (the correlation between two scales 
should be lower than their reliability coefficients, as meas-
ured by Cronbach’s alpha); and construct validity in its 
two components: the convergent or external validity which 
examines the correlation of the JAMAR sub-scales with 
the six JIA core set variables, with the addition of the par-
ent assessment of disease activity and pain by the Spear-
man’s correlation coefficients (r) [17] and the discriminant 
validity, which assesses whether the JAMAR discriminates 
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between the different JIA categories and healthy children 
[18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Chilean Spanish parent and patient 
versions of the JAMAR are available upon request to 
PRINTO.
Results
Cross‑cultural adaptation
The Chilean Spanish JAMAR was fully cross-culturally 
adapted from the standard English version with 2 forward 
and 2 backward translations with a concordance for 118/123 
(95.9%) translations lines for the parent version and 113/120 
(94.2%) lines for the child version. Of the 123 lines in the 
parent version of the JAMAR, 117 (95.12%) were under-
stood by at least 80% of the 10 parents tested (median 100%; 
range 60–100%). In the patient version of the JAMAR, 
103/120 (85.8%) lines were understood by at least 80% of 
the children (median 100%; range 50–100%). Lines 64, 65, 
68, 69, 88, and 114 of the parent version of the JAMAR and 
lines 4, 5, 10, 50, 55, 62–70, 94, 107, 111 of the child ver-
sion were modified according to parent patients suggestions.
Demographic and clinical characteristics 
of the subjects
A total of 49 JIA patients were enrolled at the paediatric 
rheumatology centre of the Hospital Dr. Exequiel Gonza-
lez Cortes in Santiago. At the study unit, it was possible to 
enroll only 70 healthy children as a control cohort.
In the 49 JIA subjects, the JIA categories were 12.2% 
with systemic arthritis, 24.5% with oligoarthritis, 22.5% 
with RF negative polyarthritis, 2.0% with RF positive pol-
yarthritis, 8.2% with enthesitis related arthritis and 30.6% 
with undifferentiated arthritis (Table 1). Notably, none of 
the enrolled JIA patients is affected with psoriatic arthritis.
All the 119 subjects had the parent version of the JAMAR 
completed by a parent (49 from parents of JIA patients and 
70 from parents of healthy children). The JAMAR was com-
pleted by 102/119 (85.7%) mothers and 17/119 (14.3%) 
fathers. The child version of the JAMAR was completed by 
all the 70 children aged 7.0 or older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing results section refers mainly to the parent’s version of 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values.
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items, whereas a reduced number of response 
choices was used for PF items 11 and 13.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items (data 
not shown).
The median number of items marked as not applicable 
was 0% (0–0%) for the PF and 1% (0–1%) for the HRQoL 
items.
Floor and ceiling effect
The median floor effect was 44.9% (38.8–67.3%) for the PF 
items, 22.4% (22.4–28.6%) for the HRQoL PhH items, and 
22.4% (18.4–26.5%) for the HRQoL PsH items. The median 
ceiling effect was 10.2% (6.1–14.3%) for the PF items, 
16.3% (16.3–20.4%) for the HRQoL PhH items, and 14.3% 
(14.3–14.3%) for the HRQoL PsH items. The median floor 
effect was 24.5% for the pain VAS, 30.6% for the disease 
activity VAS and 16.3% for the well-being VAS. The median 
ceiling effect was 0% for the pain VAS, 0% for the disease 
activity VAS and 4.1% for the well-being VAS.
Equal items–scale correlations (second Likert 
assumption)
Pearson items–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 93% of the PF 
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items, with the exception of PF item 15, and for 100% of the 
HRQoL items, with the exception of HRQoL items 1 and 5.
Items internal consistency (third Likert assumption)
Pearson items–scale correlations were ≥ 0.4 for 100% of 
items of the PF and 100% of items of the HRQoL.
Table 1  Descriptive statistics (medians, 1st and 3rd quartiles or absolute frequencies and %) for the 49 JIA patients
Data related to the JAMAR refers to the 49 JIA patients and to the 70 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA Anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL Health Related Quality of Life (total score ranges from 0 to 30), PhH Physical Health (total score ranges 
from 0 to 15), PsH Psychosocial Health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic 
(N = 6)
Oligoarthritis 
(N = 12)
RF− poly-
arthritis 
(N = 11)
RF+ poly-
arthritis (N = 1)
Enthesitis 
related arthritis 
(N = 4)
Undifferenti-
ated arthritis 
(N = 15)
All JIA patients 
(N = 49)
Healthy (N = 70)
Female 1 (16.7%) 9 (75%) 10 (90.9%) 1 (100%) 3 (75%) 9 (60%) 33 (67.3%) 31 (44.3%)*
Age at visit 8.5 (7.8–9.5) 16 (11.5–16.7) 13.6 (11.4–
14.1)
11.4 (11.4–
11.4)
13.1 (12.8–
14.9)
13.8 (10.2–
15.3)
13.4 (10.8–
15.3)*
13.9 (12.9–15)
Age at onset 6.3 (4.2–7.1) 8.1 (3.5–11.1) 8.8 (4.2–12.4) 6.4 (6.4–6.4) 9.7 (7.3–10.1) 9.9 (5.3–12.3) 7.3 (4.8–10.5)
Disease duration 2.2 (1.1–3.5) 6.4 (4.8–7.7) 4.6 (3.3–6.6) 5 (5–5) 4.8 (2.7–7.5) 3 (1.6–4.7) 4.3 (2.3–6.6)*
ESR 20 (20–20) 14 (12–15) 6 (6–6) 19 (19–19) 10 (9–15) 15 (9–22) 15 (9–20)
MD VAS 2.3 (1–4) 0.3 (0–2.8) 2.5 (0.5–3) 7.5 (7.5–7.5) 3.5 (2.8–3.8) 4 (3–5) 3 (0.5–4)*
No. swollen joints 1.5 (0–4) 0 (0–1) 3 (0–5) 18 (18–18) 2 (1–2.5) 4 (2–6) 2 (0–4)*
No. joints with 
pain
3 (0–4) 0 (0–2) 4 (0–8) 24 (24–24) 3.5 (1.5–4) 5 (3–9) 4 (0–6)*
No. joints with 
LOM
3 (2–4) 1.5 (0–2) 4 (1–9) 24 (24–24) 3 (1.5–4) 6 (4–10) 4 (1–6)*
No. active joints 3 (0–4) 0 (0–2) 4 (0–8) 22 (22–22) 2.5 (1–3.5) 5 (3–8) 3 (0–5)*
Active systemic 
features
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
ANA status 0 (0%) 5 (41.7%) 0 (0%) 0 (0%) 0 (0%) 2 (13.3%) 7 (14.3%)
Uveitis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
PF total score 12.5 (1–16) 5.5 (3.5–11) 9 (1–14) 41 (41–41) 11.5 (6–19) 13 (9–26) 10 (5–17) 0 (0–1)#
Pain VAS 3.8 (0–5) 0.3 (0–6) 1.5 (0–4.5) 9.5 (9.5–9.5) 3 (2.8–4.5) 5.5 (2–7) 3.5 (0.5–6)
Disease activity 
VAS
3.8 (0–5) 0.5 (0–6) 4 (0–5) 9.5 (9.5–9.5) 4 (2–6.5) 7 (2.5–8) 4 (0–6)
Well-being VAS 4.5 (2–5) 1.3 (0.3–5.8) 3.5 (0.5–5) 10 (10–10) 5.3 (3.5–6.8) 6 (3–8.5) 4.5 (1–6.5)
HRQoL PhH 8 (2–9) 3.5 (0–9.5) 5 (2–7) 15 (15–15) 6 (6–8) 9 (4–14) 6 (2–10) 0 (0–1)#
HRQoL PsH 4 (4–4) 4.5 (3.5–7.5) 5 (1–8) 15 (15–15) 7 (4.5–10) 5 (4–12) 5 (4–9) 1 (0–1)#
HRQoL total 
score
11.5 (6–16) 8 (4–17) 10 (3–16) 30 (30–30) 14 (10.5–18) 15 (7–24) 12 (7–19) 1 (0–1)#
Pain/swell. in > 1 
joint
4 (66.7%) 6 (50%) 6 (54.5%) 1 (100%) 4 (100%) 13 (86.7%) 34 (69.4%) 4 (5.7%)#
Morning stiff-
ness > 15 min
3 (50%) 4 (33.3%) 6 (54.5%) 1 (100%) 2 (50%) 13 (86.7%) 29 (59.2%) 0 (0%)#
Subjective remis-
sion
4 (66.7%) 4 (33.3%) 6 (54.5%) 1 (100%) 4 (100%) 13 (86.7%) 32 (65.3%)*
In treatment 6 (100%) 6 (50%) 10 (90.9%) 1 (100%) 4 (100%) 14 (93.3%) 41 (83.7%)*
Reporting side 
effects
2 (33.3%) 3 (50%) 3 (30%) 1 (100%) 3 (75%) 8 (57.1%) 20 (48.8%)
Taking medica-
tion regularly
6 (100%) 5 (83.3%) 8 (80%) 1 (100%) 2 (50%) 10 (71.4%) 32 (78%)
With problems 
attending school
3 (75%) 3 (33.3%) 5 (55.6%) 1 (100%) 3 (100%) 8 (80%) 23 (63.9%) 1 (1.5%)#
Satisfied with dis-
ease outcome
1 (16.7%) 7 (58.3%) 5 (45.5%) 0 (0%) 0 (0%) 2 (13.3%) 15 (30.6%)*
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.96 for PF-LL, 0.97 for PF-HW, 
0.89 for PF-US. Cronbach’s alpha was 0.96 for HRQoL-
PhH and 0.90 for HRQoL-PsH.
Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of 
the questionnaires was lower than the Cronbach’s alpha for 
all the items (except for PF item 13).
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL Health Related Quality of Life, PhH Physical Health, PsH Psychosocial Health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent (N = 49/119) Child (N = 49/119)
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 44.9% 38.6%
 HRQoL PhH 22.4% 20.0%
 HRQoL PsH 22.4% 21.4%
 Pain VAS 24.5% 15.7%
 Disease activity VAS 30.6% 21.4%
 Well-being VAS 16.3% 17.1%
Ceiling effect, median
 PF 10.2% 2.9%
 HRQoL PhH 16.3% 8.6%
 HRQoL PsH 14.3% 7.1%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 4.1% 0.0%
Items with equivalent item-scale correlation 93% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Items with items–scale correlation ≥ 0.4 100% for PF, 100% for HRQoL 100% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.96 0.93
 PF-HW 0.97 0.94
 PF-US 0.89 0.88
 HRQoL-PhH 0.96 0.95
 HRQoL-PsH 0.90 0.90
Items with item-scale correlation lower than the Cronbach alpha 93% for PF, 100% for HRQoL 87% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.68 0.62
 HRQoL-PhH 0.85 0.72
 HRQoL-PsH 0.78 0.73
Spearman correlation with JIA core-set variables, median
 PF 0.8 0.8
 HRQoL PhH 0.7 0.8
 HRQoL PsH 0.6 0.6
 Pain VAS 0.8 0.8
 Disease activity VAS 0.7 0.8
 Well-being VAS 0.7 0.8
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Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after 
a median of 7 days (7–8 days). The intraclass correlation 
coefficients (ICC) for the PF total score showed a substantial 
reproducibility (ICC 0.68). The ICC for the HRQoL PhH 
showed an almost perfect reproducibility (ICC 0.85) while 
the ICC for the HRQoL PsH showed a substantial reproduc-
ibility (ICC 0.78).
Convergent validity
The Spearman correlation of the PF total score with the JIA 
core set of outcome variables ranged from 0.7 to 0.9 (median 
0.8). The PF total score best correlation was observed with 
the parent assessment of pain (r = 0.9, p < 0.001). For the 
HRQoL, the median correlation of the PhH with the JIA 
core set of outcome variables ranged from 0.6 to 0.9 (median 
0.7), whereas for the PsH ranged from 0.5 to 0.7 (median 
0.6). The PhH showed the best correlation with the par-
ent’s assessment of disease activity (r = 0.9, p < 0.001) and 
the PsH with the parent global assessment of well-being 
(r = 0.8, p < 0.001). The median correlations between the 
pain VAS, the well-being VAS, and the disease activity VAS 
and the physician-centred and laboratory measures were 0.8 
(0.6–0.8), 0.7 (0.6–0.8), 0.7 (0.6–0.8), respectively.
Discussion
In this study, the Chilean Spanish version of the JAMAR 
was cross-culturally adapted from the original standard Eng-
lish version with two forward and two backward transla-
tions. According to the results of the validation analysis, the 
Chilean Spanish parent and patient versions of the JAMAR 
possess satisfactory psychometric properties. The disease-
specific components of the questionnaire discriminated well 
between patients with JIA and healthy controls.
Psychometric performances were good for all domains of 
the JAMAR and the overall internal consistency was excel-
lent for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged were strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents.
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions of 
daily life that were not previously considered by other HRQoL 
tools. This may provide useful information for intervention and 
follow-up in health care.
In conclusion, the Chilean Spanish version of the JAMAR 
was found to have satisfactory psychometric properties and 
it is, thus a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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